Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,091 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dementia Alzheimers Clear all

Conditions: Alzheimer Disease
Interventions: Raloxifene; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 55 Years to 90 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Alzheimer's Disease
Interventions: VHB937, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 22
States / cities: Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more

Conditions: Alzheimer's Disease
Interventions: Placebo, ABT-126, donepezil; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 55 Years to 90 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Fresno, California • West Palm Beach, Florida • Indianapolis, Indiana

Conditions: Alzheimer Disease, Agitation in Dementia
Interventions: hMSC; Biological
Lead sponsor: Bernard (Barry) Baumel; Other
Eligibility: 55 Years to 90 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Alzheimer Disease, Parkinson Disease, Inflammation
Interventions: GE180 PET Scan; Drug
Lead sponsor: Aaron Ritter, MD; Other
Eligibility: 55 Years to 90 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Alzheimer Disease
Interventions: Family-centered Function-focused Care (Fam-FFC); Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 65 Years and older
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 3
States / cities: Lancaster, Pennsylvania • Philadelphia, Pennsylvania • West Chester, Pennsylvania

Conditions: Alzheimer's Disease Prevention
Interventions: Aerobic vs. Non-Aerobic exercise; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 65 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Interventions: Not listed
Lead sponsor: University of Southern California; Other
Eligibility: 55 Years to 90 Years
Enrollment: 1,141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2024
U.S. locations: 54
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 42 more

Conditions: Alzheimer Disease, Mild Cognitive Impairment
Interventions: Data-Driven Clinical Recommendations, Coached Data-Driven Clinical Recommendations; Behavioral
Lead sponsor: Saint John's Cancer Institute; Other
Eligibility: 50 Years to 80 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Alzheimer Disease, Dementia, Dementia, Vascular, Pain
Interventions: hydrocodone/APAP w placebo PRN, hydrocodone/APAP, placebo with hydrocodone/APAP PRN; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 55 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 3
States / cities: Tuscaloosa, Alabama

Conditions: Dementia, Alzheimer Disease, Lewy Body Disease, Vascular Dementia, Frontotemporal Dementia, Mixed Dementia
Interventions: Kinto Care Coaching; Behavioral
Lead sponsor: Kinto; Industry
Eligibility: 18 Years and older
Enrollment: 495 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Psychosis Associated With Alzheimer's Disease
Interventions: KarXT; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 148
States / cities: Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 92 more

Conditions: Dementia, Vascular, Alzheimer Disease, Dementia, Mixed
Interventions: LEAD IT! Programming; Behavioral
Lead sponsor: Hopeful Aging; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Winchester, Massachusetts

Conditions: Dementia, Mixed, Dementia Mild, Dementia Moderate, Traumatic Brain Injury, Alzheimer Disease
Interventions: Telehealth-delivered Care Coordination Program; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Alzheimer's Disease, Hypertension
Interventions: Ramipril, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 40 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Alzheimers Disease
Interventions: RO7126209, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 15
States / cities: Atlantis, Florida • Clermont, Florida • Lady Lake, Florida + 12 more

Conditions: Alzheimer Disease
Interventions: Extra virgin olive oil; Dietary Supplement
Lead sponsor: Augusta University; Other
Eligibility: 30 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Lewy Body Dementia (LBD), Alzheimer Dementia (AD)
Interventions: C-11 ER-176, Blood Test; Drug · Diagnostic Test
Lead sponsor: Val Lowe; Other
Eligibility: 60 Years and older
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Alzheimer Disease
Interventions: TMS stimulation with X-Torp task, TMS-Stimulation with MindMotion Go, TMS-Sham with X-Torp task, TMS-Sham with MindMotion Go; Device
Lead sponsor: Ali Rezai; Other
Eligibility: 50 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Mild Cognitive Impairment, MCI, Aging, Alzheimer's Disease, AD
Interventions: Methylene Blue, FD&C Blue # 2, Phenazopyridine hydrochloride; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 45 Years to 89 Years
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Alzheimer Disease, Mild Cognitive Impairment, Adherence
Interventions: Improving Cognitive Aging through Nutrition (ICAN) Adherence Program, Improving Cognitive Aging through Nutrition, Mediterranean diet; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 55 Years to 85 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions: Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2020
U.S. locations: 10
States / cities: Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 7 more

Conditions: Alzheimer's Disease
Interventions: KarXT, KarX-EC, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 31
States / cities: Fullerton, California • Irvine, California • Los Angeles, California + 28 more

Conditions: Sleep Disordered Breathing, Alzheimer's Disease
Interventions: Continuous positive airway pressure (CPAP); Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 50 Years and older
Enrollment: 235 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: New York, New York

Search by objective public record fields.

Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease

Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.

The Relationship Between Neuropsychological Testing and MRI, PET and COBRE - Project 1: AIM 2 (GE-180)

A Family-centered Intervention for Acutely-ill Persons With Dementia

Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study

Alzheimer's Disease Neuroimaging Initiative 3

The PREVENTION Trial: Precision Recommendations to Optimize Neurocognition

Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)

Efficacy Study of Kinto Care Coaching for Dementia Family Caregivers

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

LEAD IT! An App to Enable Persons With Early Stage Dementia to Lead Group Activities for Their Peers

An Innovative Supportive Care Model for Dementia and Traumatic Brain Injury

Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

Does EVOO Induce Gene and Metabolic Changes in Healthy Subjects

Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia and Related Dementias

Application of TMS Coupled With VR for Slowing the Rate of Cognitive Decline in Patients With Alzheimer's Disease

Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease

A Scalable Nutrition Adherence Intervention

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Sleep, Aging and Risk for Alzheimer's Disease